Journal
MOLECULAR CANCER
Volume 6, Issue -, Pages -Publisher
BMC
DOI: 10.1186/1476-4598-6-6
Keywords
-
Categories
Funding
- NCI NIH HHS [CA87728, CA89019, R01 CA087728, P30 CA013148, P50 CA089019] Funding Source: Medline
Ask authors/readers for more resources
Background: Osteopontin (OPN), a secreted phosphoglycoprotein, has been strongly associated with tumor progression and aggressive cancers. MDA-MB-435 cells secrete very high levels of OPN. However metastasis-suppressed MDA-MB-435 cells, which were transfected with breast cancer metastasis suppressor 1 ( BRMS1), expressed significantly less OPN. BRMS1 is a member of mSin3-HDAC transcription co-repressor complex and has been shown to suppress the metastasis of breast cancer and melanoma cells in animal models. Hence we hypothesized that BRMS1 regulates OPN expression. Results: The search for a BRMS1-regulated site on the OPN promoter, using luciferase reporter assays of the promoter deletions, identified a novel NF-kappa B site (OPN/NF-kappa B). Electrophoretic mobility shift assays and chromatin immunoprecipitations (ChIP) confirmed this site to be an NF-kappa B-binding site. We also show a role of HDAC3 in suppression of OPN via OPN/NF-kappa B. Conclusion: Our results show that BRMS1 regulates OPN transcription by abrogating NF-kappa B activation. Thus, we identify OPN, a tumor-metastasis activator, as a crucial downstream target of BRMS1. Suppression of OPN may be one of the possible underlying mechanisms of BRMS1-dependent suppression of tumor metastasis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available